Comparing Prescription Opioids, Methadone, and Heroin Rates from the Treatment Episode Data Set to the RADARS® System Treatment Center Programs

HA Olsen¹, SG Severton¹, J Schwarz¹, M Ellis², TJ Cicero², RC Dart¹

¹Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority
²Washington University, St. Louis, Missouri

Abstract

Background
The Researched, Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System provides timely product-specific, national surveillance data on prescription opioid abuse. This analysis assesses whether annual abuse trends observed in the RADARS System treatment center programs are similar to trends from the Treatment Episodes Data Set (TEDS).

Methods
The RADARS System Opioid Treatment Program (OTP) enrolls individuals entering treatment for opioid use disorders at primarily medication-assisted programs and the Survey of Key Informants’ Patients Program (SKIP) enrolls individuals entering treatment for opioid use disorders primarily private substance abuse programs. TEDS includes records on admissions to substance abuse treatment centers for all substances, including prescription and non-prescription opioids.

Results
From 2008 through 2014, OTP and SKIP were compared to data from the TEDS 2014 national report for endorsement of use in the past month of drugs common to all three surveys: prescription opioids, heroin, and methadone. Population rates for OTP and SKIP were compared as the total number of endorsements divided by the sum of the population of 3-digit ZIP codes where at least one respondent resided. A Pearson’s correlation coefficient was calculated to test the relationship between RADARS System programs and TEDS population trends over time for prescription opioids excluding methadone, methadone, and heroin abuse.

Conclusions
Trends in both RADARS System programs appear to track well with national data from TEDS for both prescription opioid and methadone.

Introduction
Cicero, Inciardi, and Muñoz¹ note that surveillance systems, in addition to media reports, were early indicators of the prescription opioid abuse epidemic. They note that abuse of extended release products, such as OxyContin®, proved unexpected given preclinical and clinical studies suggesting lower abuse potential¹. The discrepancy in these results highlight the importance of surveillance systems in measuring the intended and unintended impact of interventions aimed at reducing prescription opioid abuse (e.g. abuse deterrent technologies). The Researched, Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System provides timely product-specific, national and regional surveillance data on prescription and illicit opioid abuse. This analysis assesses whether annual abuse trends observed in the RADARS System Treatment Center Programs are similar to national trends from the Treatment Episodes Data Set (TEDS).

Discussion and Conclusion

Methods, continued

Statistical Analysis
From 2008 through 2014, OTP and SKIP were compared to data from the TEDS 2014 national report for endorsement of use in the past month of drugs common to all three surveys: prescription opioids, heroin, and methadone. Population rates for OTP and SKIP were calculated as the total number of endorsements divided by the sum of the population of the three-digit ZIP codes where at least one respondent resided. These population rates were compared to rates calculated from Table 1.1a in the TEDS 2014 national report¹. The numerator represented the number of respondents who reported a primary drug of heroin, non-prescription methadone, and other opiates/synthetics. A Pearson’s correlation coefficient was calculated to test the relationship between RADARS System programs and TEDS population rates over time for prescription opioids excluding methadone, methadone, and heroin abuse.

Results
In OTP, prescription opioids (r=0.82), methadone (r=0.88) and heroin (r=0.86) were strongly correlated with TEDS data. In SKIP, prescription opioids (r=0.85) and methadone (r=0.88) were strongly correlated with TEDS data and heroin showed a negative correlation (r=-0.40). In TEDS 65% of individuals entering treatment for opioid abuse reported heroin as their primary drug, whereas, 54% in OTP and 31% in SKIP reported heroin as their primary drug.

Conclusions
Trends in both RADARS System programs appear to track well with national data from TEDS for both prescription opioid and methadone.

Discussion and Conclusion

Trends in both RADARS System OTP and SKIP Programs appear to track well with national data from TEDS for both prescription opioids and methadone. Correlations with heroin were strong in the OTP but negatively correlated with rates in the SKIP. The discrepancy in trends is likely due to differences in the populations. A smaller proportion of the SKIP program report heroin as their primary drug, therefore changes in abuse patterns in the SKIP may reflect changes in abuse among a sample of primarily prescription opioid users. In addition, discrepancies in rates may also be because the TEDS survey samples from individuals entering substance abuse treatment for substances other than opioids (e.g. alcohol and cocaine).

References
2. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2004-2014. National Admissions Survey of Key Informants’ Patients Program (SKIP) enrolls individuals entering treatment primarily at private substance abuse treatment programs. TEDS includes records on admissions to substance abuse treatment centers nationally for all substances. This analysis focuses on the primary substance reported in TEDS.

Conflict of Interest
The authors are affiliated with the RADARS® System, an independent nonprofit post-market surveillance system that is supported by subscription fees from pharmaceutical manufacturers. None of the authors have a direct financial, commercial, or other relationship with any of the authors.

Support
The RADARS System is supported by subscriptions from pharmaceutical manufacturers, government and non-government agencies for surveillance, research and reporting services. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases and systems. Subscribers do not participate in data collection nor do they have access to the raw data.